C K Osborne

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
    C Kent Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:353-61. 2003
  2. ncbi Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial
    C K Osborne
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 20:3386-95. 2002
  3. ncbi Role of molecular and genetic markers in breast cancer treatment decisions
    C Kent Osborne
    Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:285s-287s. 2003
  4. ncbi Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
    Clin Cancer Res 11:865s-70s. 2005
  5. ncbi Estrogen receptor: current understanding of its activation and modulation
    C K Osborne
    Baylor College of Medicine, Breast Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:4338s-4342s; discussion 4411s-4412s. 2001
  6. ncbi Estrogen-receptor biology: continuing progress and therapeutic implications
    C Kent Osborne
    Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600 Houston, TX 77030, USA
    J Clin Oncol 23:1616-22. 2005
  7. ncbi Aromatase inhibitors: future directions
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 95:183-7. 2005
  8. ncbi Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
    A V Lee
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Mol Endocrinol 13:787-96. 1999
  9. ncbi Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study
    R M Elledge
    Baylor College of Medicine, Houston, TX, USA
    Int J Cancer 89:111-7. 2000
  10. ncbi HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer
    S M Townson
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 6:3788-96. 2000

Collaborators

Detail Information

Publications84

  1. ncbi Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
    C Kent Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:353-61. 2003
    ....
  2. ncbi Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial
    C K Osborne
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 20:3386-95. 2002
    ..To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment...
  3. ncbi Role of molecular and genetic markers in breast cancer treatment decisions
    C Kent Osborne
    Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:285s-287s. 2003
  4. ncbi Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
    Clin Cancer Res 11:865s-70s. 2005
    ..This process can be delayed or reversed by simultaneous treatment with growth factor pathway inhibitors. This strategy is now being tested in clinical trials...
  5. ncbi Estrogen receptor: current understanding of its activation and modulation
    C K Osborne
    Baylor College of Medicine, Breast Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:4338s-4342s; discussion 4411s-4412s. 2001
    ..Targeting growth factor pathways, in addition to ER, is a developing strategy that hypothetically may represent optimal therapy by preventing the development of resistance to endocrine therapy...
  6. ncbi Estrogen-receptor biology: continuing progress and therapeutic implications
    C Kent Osborne
    Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600 Houston, TX 77030, USA
    J Clin Oncol 23:1616-22. 2005
  7. ncbi Aromatase inhibitors: future directions
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 95:183-7. 2005
    ....
  8. ncbi Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
    A V Lee
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Mol Endocrinol 13:787-96. 1999
    ..Taken together, these data not only reinforce the concept of cross-talk between IGF- and ER-signaling pathways, but indicate that IGF molecules may be critical regulators of estrogen-mediated growth and breast cancer pathogenesis...
  9. ncbi Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study
    R M Elledge
    Baylor College of Medicine, Houston, TX, USA
    Int J Cancer 89:111-7. 2000
    ..09). Increasing ER and PgR by IHC, as by LBA, are thus significantly associated with a progressively better response and longer survival in ER(+) metastatic breast cancer. pS2 is also predictive in this setting...
  10. ncbi HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer
    S M Townson
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 6:3788-96. 2000
    ..We conclude that HET/SAF-B plays an important role in breast cancer, and we discuss possible mechanisms of the involvement of HET/SAF-B in cell proliferation and division...
  11. ncbi Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions
    H H Zhao
    Division of Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284, USA
    J Biol Chem 276:27907-12. 2001
    ..Therefore, FKHR represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type...
  12. ncbi Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients
    Jenny C Chang
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    Breast Cancer Res Treat 108:233-40. 2008
    ..008). We have established molecular profiles of sensitivity to docetaxel. RT-PCR technology provides a potential platform for a predictive test of docetaxel chemosensitivity using small amounts of routinely processed material...
  13. ncbi Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer
    G M Clark
    Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center, San Antonio 78284, USA
    Cancer Res 57:5505-8. 1997
    ..These preliminary results suggest that mitosin as assessed by IHC may be superior to SPF as a prognostic factor in node-negative breast cancer, but additional studies are necessary to validate these promising findings...
  14. ncbi Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    Grazia Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    J Natl Cancer Inst 97:1254-61. 2005
    ..As in laboratory models, lack of PR expression in ER+ tumors may be a surrogate marker of aberrant growth factor signaling that could contribute to the tamoxifen resistance observed in these tumors...
  15. ncbi Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    ..Gefitinib's ability to eliminate this cross-talk and to restore tamoxifen's antitumor effects should be tested in the clinic...
  16. ncbi Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  17. ncbi Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 12:362-7. 2003
    ..In turn, ER located in the cell membrane can activate the growth factor receptor pathways. Breast tumors with high levels of AIB1 and HER-2 may be resistant to tamoxifen because of an increase in its estrogen agonist activity...
  18. ncbi Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
    Xiaoxian Li
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
    J Natl Cancer Inst 100:672-9. 2008
    ....
  19. ncbi DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
    A A Rodriguez
    Dan L Duncan Cancer Center, Baylor College of Medicine, 1 Baylor Plaza BCM 600, Houston, TX 77030, USA
    Breast Cancer Res Treat 123:189-96. 2010
    ....
  20. ncbi Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth
    S Oesterreich
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Res 61:5771-7. 2001
    ..These data show that ERalpha is a critical requirement for IGF signaling, and to our knowledge this is the first report of functional ERalpha expression that confers estrogen-mediated growth of an ER-negative breast cancer cell line...
  21. ncbi High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer
    S Oesterreich
    Department of Medicine and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Br J Cancer 84:493-8. 2001
    ..While preliminary findings of mutations in SAFB suggest that this indeed may be a promising candidate, other potential candidate genes are located at this locus...
  22. ncbi HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study
    Grazia Arpino
    Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Clin Cancer Res 10:5670-6. 2004
    ....
  23. ncbi Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Xiaojiang Cui
    Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 23:7721-35. 2005
    ..Finally, we will consider the clinical implications of these observations...
  24. ncbi Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation
    S Oesterreich
    Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA
    Mol Endocrinol 14:369-81. 2000
    ..Furthermore, our data showing that HET/SAF-B binds to ER particularly strongly in the presence of tamoxifen suggests that it may be important for the antagonist effect of tamoxifen...
  25. ncbi Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  26. ncbi Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors
    Chunhua Lu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:1825-33. 2003
    ..We examined whether ZD1839 blocks signal transduction and prevents the development of ER-negative breast cancer...
  27. ncbi Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice
    Tracy E Strecker
    Breast Center, Department of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 101:107-13. 2009
    ..Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients. These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer...
  28. ncbi Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    ..CONCLUSION: The molecular pathways driving tumor growth can change as the tumor progresses. Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance...
  29. ncbi Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Chad J Creighton
    The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Cancer Res 68:7493-501. 2008
    ..Over time, the molecular phenotype of breast cancer can change...
  30. ncbi Telomerase activity and survival of patients with node-positive breast cancer
    G M Clark
    Department of Medicine, The University of Texas Health Science Center at San Antonio, 78284 7884, USA
    J Natl Cancer Inst 89:1874-81. 1997
    ....
  31. ncbi Steroid hormone receptors in breast cancer management
    C K Osborne
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Breast Cancer Res Treat 51:227-38. 1998
    ..In summary, ER and PR status are important biomarkers that help physicians individualize therapy...
  32. ncbi Selective estrogen receptor modulators: structure, function, and clinical use
    C K Osborne
    Breast Center and Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 18:3172-86. 2000
    ..Other SERMs are in development, with the goal of reducing toxicity and/or improving efficacy, and future agents have the potential of providing a new paradigm for maintaining the health of women...
  33. ncbi Time-dependence of hazard ratios for prognostic factors in primary breast cancer
    S G Hilsenbeck
    Department of Medicine, University of Texas Health Science Center at San Antonio, 78284 7884, USA
    Breast Cancer Res Treat 52:227-37. 1998
    ..Failure to recognize violations of proportional hazards can lead to both over- and under-estimation of the effects of important prognostic factors...
  34. ncbi Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
    C K Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Br J Cancer 90:S2-6. 2004
    ..Preclinical and clinical study data are presented in support of the novel mechanism of action of this new type of ER antagonist...
  35. ncbi Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen
    G Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 23:4687-94. 2005
    ..Thus, other reasons should be considered to clarify the failure of tamoxifen to reduce the incidence of CBC in patients with a receptor-negative PBC...
  36. ncbi Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
    Yee-Lu Tham
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:279-84. 2005
    ..Docetaxel acts therapeutically by inducing apoptosis and this can be used as a marker of response...
  37. ncbi Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor
    Ashby J Morrison
    Department of Molecular and Cellular Biology and The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 17:1543-54. 2003
    ....
  38. ncbi Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor
    Shiming Jiang
    The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 20:311-20. 2006
    ..The coexpression of these proteins in breast cancer specimens, and the combined recruitment (and release) of SAFB1/2 and N-CoR furthermore suggests that this interaction has functional relevance...
  39. ncbi Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Grazia Arpino
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Natl Cancer Inst 99:694-705. 2007
    ..We investigated whether blockade of all HER homo- and heterodimer pairs by combined treatment with several inhibitors could more effectively inhibit tumor growth in such models...
  40. ncbi A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3β Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone
    R J Hartmaier
    University of Pittsburgh Cancer Institute, 204 Craft Avenue, Pittsburgh, Pennsylvania 15213
    Mol Endocrinol 26:220-7. 2012
    ....
  41. ncbi Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene
    M D Martin
    Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 61:3578-80. 2001
    ..Toh et al., J. BIOL: CHEM:, 269: 22958-22963, 1994.), mapped to the center of our 1.6-Mb target region. Thus, MTA1 represents a strong candidate for this breast cancer metastasis-promoting gene...
  42. ncbi Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance
    Grazia Arpino
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Endocr Rev 29:217-33. 2008
    ....
  43. ncbi Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer
    Rachel Schiff
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Breast Cancer Res 7:205-11. 2005
    ..Preclinical data suggest that blockade of selected growth factor receptor signaling can overcome this type of resistance, and this strategy is already being tested in clinical trials...
  44. ncbi Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial
    Susan G Hilsenbeck
    Breast Center and Department of Medicine, Baylor College of Medicine, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Clin Cancer Res 12:1049s-1055s. 2006
    ..We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy...
  45. ncbi Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy
    C Kent Osborne
    The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 14:458-65. 2005
    ....
  46. ncbi Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Breast Center room N1230, One Baylor Plaza MS 600, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 56:10-20. 2005
    ....
  47. ncbi Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer
    Syed K Mohsin
    Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:205-11. 2005
    ..Proliferation, determined by Ki67 staining, was not significantly changed. Clinical trials of this type are difficult to carry out and modifications in trial design are needed to make this process more efficient...
  48. ncbi Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
    ..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective...
  49. ncbi Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Jenny C Chang
    Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA
    Lancet 362:362-9. 2003
    ..Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel...
  50. ncbi Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
    Jenny C Chang
    Breast Center, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:1169-77. 2005
    ..Chemotherapy for operable breast cancer decreases the risk of death. Docetaxel is one of the most active agents in breast cancer, but resistance or incomplete response is frequent...
  51. ncbi Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
    Syed K Mohsin
    Breast Center at Baylor College of Medicine/The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:2460-8. 2005
    ..02). CONCLUSION: In primary breast cancers, trastuzumab substantially induces apoptosis, providing a molecular explanation for both its therapeutic efficacy and its successful combination with cytotoxic chemotherapy...
  52. ncbi Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:447S-54S. 2003
    ..Thus, the interactions of these diverse elements are essential considerations in defining new predictive and therapeutic tools...
  53. ncbi Low SAFB levels are associated with worse outcome in breast cancer patients
    Stephanie Hammerich-Hille
    Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 121:503-9. 2010
    ..This study shows that low SAFB protein levels predict poor prognosis of breast cancer patients, suggesting critical functions of SAFB1 and SAFB2 in breast cancer cells...
  54. ncbi Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
    Valerie-Jeanne Bardou
    Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:1973-9. 2003
    ..Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients...
  55. ncbi Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
    Mothaffar F Rimawi
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cancer 116:1234-42. 2010
    ..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy...
  56. ncbi Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer
    Torsten A Hopp
    Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Clin Cancer Res 10:7490-9. 2004
    ..The clinical value of the second recently identified ER isoform, called ER-beta, is less clear, and there is currently conflicting data concerning its potential role as a prognostic or predictive factor...
  57. ncbi The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth
    Jana Divisova
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 98:315-27. 2006
    ..This data supports previous studies indicating a role for GH/IGF in mammary gland development, and suggests that pegvisomant maybe useful for the prevention and/or treatment of estrogen receptor positive breast cancer...
  58. ncbi Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
    Michelle D Martin
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Breast Cancer Res Treat 95:7-12. 2006
    ..Tamoxifen and/or anthracylcene-based chemotherapies eliminated all MTA1 associations with clinical outcome, suggesting MTA1 overexpression predicts early disease relapse, but sensitizes breast tumors to systemic therapies...
  59. ncbi Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters
    Suzanne A W Fuqua
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 63:2434-9. 2003
    ..These results suggest that ERbeta expression is not a surrogate for ERalpha in clinical breast tumors and, as such, could be a useful biomarker in its own right...
  60. ncbi Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth
    Yongmin Liu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston Texas, TX 77030, USA
    Oncogene 21:7680-9. 2002
    ..These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer...
  61. ncbi Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
    L Malorni
    Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res Treat 136:795-804. 2012
    ..Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival...
  62. ncbi Systemic mirnas as potential biomarkers for malignancy
    N A Healy
    Discipline of Surgery, National University of Ireland, Galway, Republic of Ireland
    Int J Cancer 131:2215-22. 2012
    ..In addition, this review questions the source of these small molecules in the bloodstream and how they may possibly play a role in the future detection of cancer as either prognostic or predictive markers...
  63. ncbi Attribution of blame, self-forgiving attitude and psychological adjustment in women with breast cancer
    Lois C Friedman
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
    J Behav Med 30:351-7. 2007
    ..89, p = .004, respectively). Patients may benefit from a discussion with their oncologists and other healthcare providers about self-forgiveness and the potential benefits of reducing self-blame to facilitate adjustment to breast cancer...
  64. ncbi Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
    ..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse...
  65. ncbi Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
    Suleiman Massarweh
    Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 68:826-33. 2008
    ..This study provides a rationale to combine HER inhibitors with tamoxifen in clinical studies, even in tumors that do not initially overexpress EGFR/HER2...
  66. ncbi Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:443S-6S. 2003
  67. ncbi Enhanced gene expression in breast cancer cells in vitro and tumors in vivo
    Huanzhang Lu
    Center for Cell and Gene Therapy, National Cancer Institute, National Institutes of Health, Building 10, Room 2A27, Bethesda, Maryland 20892, USA
    Mol Ther 6:783-92. 2002
    ..Furthermore, expression profiling can facilitate the design of optimal expression plasmids for use in specific cancers...
  68. ncbi Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of
    Saul E Rivkin
    Swedish Cancer Institute, Seattle, Washington, USA
    Cancer 97:21-9. 2003
    ..CONCLUSIONS: The authors conclude that, after 20 years of follow-up, adjuvant chemotherapy with CMFVP remains superior to L-PAM for the treatment of patients with lymph node positive breast carcinoma...
  69. ncbi Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    John F R Robertson
    Department of Surgery, Nottingham City Hospital, Nottingham, United Kingdom
    Cancer 98:229-38. 2003
    ....
  70. ncbi Spreading the word, but not too thinly
    Anthony Howell
    Lancet 363:165-6. 2004
  71. ncbi Insights into the role of progesterone receptors in breast cancer
    Suzanne A W Fuqua
    J Clin Oncol 23:931-2; author reply 932-3. 2005
  72. ncbi Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer
    Lori J Pierce
    Southwest Oncology Group, San Antonio, TX, USA
    J Clin Oncol 23:24-9. 2005
    ..04; P = .54). CONCLUSION: The current analysis does not suggest an adverse effect on local or systemic control with CONC versus SEQ TAM and RT in node-negative breast cancer. A randomized trial is encouraged to validate these results...
  73. ncbi Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
    Anthony Howell
    Christie Hospital and Holt Radium Institute, Manchester, UK
    J Clin Oncol 22:1605-13. 2004
    ....
  74. ncbi Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
    ..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established...
  75. ncbi Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
    Laura F Hutchins
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 23:8313-21. 2005
    ..05). CONCLUSION: CAF did not improve DFS compared with CMF; there was a slight effect on OS. Given greater toxicity, we cannot conclude CAF to be superior to CMF. TAM is effective in HR-positive disease, but not in HR-negative disease...
  76. ncbi Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance
    Susan Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Breast Cancer Res Treat 95:229-33. 2006
    ..Larger validation studies are necessary to define and refine patterns for different agents...
  77. ncbi Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Suleiman Massarweh
    Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 66:8266-73. 2006
    ..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal...
  78. ncbi The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer
    Xiao Jun Ma
    AviaraDx Inc, Carlsbad, CA, USA
    J Clin Oncol 24:4611-9. 2006
    ..Confirmation in larger independent patient cohorts was needed to fully validate their clinical utility...
  79. ncbi Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer
    Li Hua Wang
    Basic Research Program, SAIC Frederick, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    Cancer Cell 10:487-99. 2006
    ..DIBA does not affect phosphorylation of HER2, MAPK, AKT, and AIB1, suggesting that DIBA-modified ERalpha may induce a switch from agonistic to antagonistic effects of TAM on resistant breast cancer cells...
  80. ncbi Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
    Anthony Howell
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Cancer 104:236-9. 2005
    ..The authors reported the overall survival results from these studies...
  81. ncbi Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 11:861s-4s. 2005
  82. ncbi Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)
    Kishan J Pandya
    University of Rochester, James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Am J Clin Oncol 30:113-25. 2007
    ....
  83. ncbi Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)
    Hannah M Linden
    Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 25:656-61. 2007
    ....
  84. ncbi Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'
    Marc E Lippman
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109-0368, USA
    Breast Cancer Res Treat 90:1-3. 2005